Intervention Protocol

Chinese herbal medicines for adverse events of transarterial chemoembolization in patients with primary liver cancer

  1. Xiao-Qian Li1,*,
  2. Qinghui Zhou1,
  3. Jian Ping Liu2,
  4. Kun-Ming Tao3,
  5. Hongyun Chen1,
  6. Changquan Ling1

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 12 SEP 2012

Assessed as up-to-date: 16 JUN 2012

DOI: 10.1002/14651858.CD010065


How to Cite

Li XQ, Zhou Q, Liu JP, Tao KM, Chen H, Ling C. Chinese herbal medicines for adverse events of transarterial chemoembolization in patients with primary liver cancer (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010065. DOI: 10.1002/14651858.CD010065.

Author Information

  1. 1

    Changhai Hospital, Second Military Medical University, Department of Traditional Chinese Medicine, Shanghai, Shanghai, China

  2. 2

    Beijing University of Chinese Medicine, Centre for Evidence-Based Chinese Medicine, Beijing, China

  3. 3

    Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Department of Anesthesiology, Shanghai, Shanghai, China

*Xiao-Qian Li, Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Room 1407, Building of Science and Technology, Changhai Hospital, 168 Changhai Road, Shanghai, Shanghai, 200433, China. jcimlxq@yahoo.cn.

Publication History

  1. Publication Status: New
  2. Published Online: 12 SEP 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the benefits and harms of CHM on any adverse events or adverse effects caused by TACE when used for treatment of patients with primary liver cancer.